Indeed, our finding that baseline hippocampal volume moderates the longitudinal association between depressive symptoms and cognition supports a role for related pathways, which could include tau-mediated neurodegeneration, hypercortisolemia, or inflammation as potential intervention targets. This evidence concerns the gene MAPT and adrenal gland hyperfunction.